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Abbreviations
ARB Angiotensin receptor blocker
RAAS Renin–angiotensin–aldosterone system
To the Editor: Schjoedt et al. [1] convincingly demonstrated
that at group level a daily dose of 40 mg of the ACE
inhibitor lisinopril provides maximum reduction of protein-
uria in patients with type 1 diabetes and nephropathy. The
importance of the issue of dose is widely appreciated, but it
is surprising how little effort has been made to find the
optimal dose of a single agent, while numerous studies have
been performed worldwide to test the additional anti-
proteinuric benefit of dual renin–angiotensin–aldosterone
system (RAAS) blockade (angiotensin converting enzyme
inhibitor plus angiotensin receptor blocker [ARB]). The
authors must therefore be acknowledged for their contribution.
Does, however, a maximal effect at a dose of 40 mg in a
group imply that 40 mg has a maximal effect in all
individual patients? We would suggest not. In our experi-
ence in non-diabetic patients with overt proteinuria, the
dose of lisinopril required for maximal anti-proteinuric
effect varies between patients [2]. Schjoedt et al. also
mention that their patients had considerably impaired renal
function. Considering the renal clearance of lisinopril,
circulating plasma levels of lisinopril were presumably
high. Thus it is possible that in patients with better
preserved glomerular filtration rate, higher daily doses of
lisinopril would be required for comparable plasma levels
of the drug and efficacy. In addition, other patient factors
such as type of renal lesion or genetic make-up could
influence inter-individual differences in drug response.
Therefore, the evidence so far does not exclude the
possibility that daily doses of lisinopril higher than 40 mg
may be required in some patients.
Nevertheless, it would be unrealistic to claim that high-
dose RAAS blockade alone has the potential to completely
reverse proteinuria in the majority of patients, not even
when given in combination with ARB. The limits may be
set not only by efficacy, but also by side effects, as
illustrated in patients with non-diabetic proteinuria on a
high dose (300 mg) of the ARB irbesartan [3]. When
lisinopril was added in incremental doses up to 40 mg,
adverse events (hyperkalaemia, cough, dizziness) occurred
in most patients.
Since the results of the Combination Treatment of
Angiotensin-II Receptor Blocker and Angiotensin-
converting-enzyme Inhibitor in Non-diabetic Renal Disease
(COOPERATE) trial have been seriously questioned [4],
and with the recent results on renal endpoints of the
Ongoing Telmisartan Alone and in Combination with
Ramipril Global Endpoint Trial (ONTARGET) in mind
[5], the issue of whether dual RAAS blockade leads to
improved long-term renal protection should be addressed in
a new randomised study, specifically designed for that
purpose. We would strongly favour a design in which dual
blockade consists of a combination of the optimal anti-
proteinuric doses in the individual patient. Until such data
are available, we propose an individualised approach, with
titration of a single drug based on the effect on proteinuria
and on blood pressure, and the extent of side effects. If
necessary, a second drug could be added and again titrated,
with careful monitoring of side effects being essential.
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